|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protein arginine methyltransferases 5 (PRMT5) represents an attractive drug target in epigenetic field for the treatment of leukemia and lymphoma.
|
30605830 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we identify that inhibiting symmetric or asymmetric dimethylation of arginine, mediated by PRMT5 and type I protein arginine methyltransferases (PRMTs), respectively, reduces splicing fidelity and results in preferential killing of SF-mutant leukemias over wild-type counterparts.
|
31408619 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study proposes a mechanism for the requirement of PRMT5 for leukemia cell survival and provides potential biomarkers for the treatment response to PRMT5 inhibitors.
|
31611688 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Protein arginine methyltransferase 5 (PRMT5) is overexpressed in many cancer types and is a promising therapeutic target for several of them, including leukemia and lymphoma.
|
30184499 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protein arginine methyltransferase 5 (PRMT5), a type II PRMT enzyme, is reported as an important therapeutic target in leukemia and lymphoma.
|
29672052 |
2018 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
|
28945229 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study provides pre-clinical rationale for targeting PRMT5 using small-molecule inhibitors in the treatment of leukemias harboring MLL rearrangements.
|
28663579 |
2018 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of one of the nine mammalian PRMTs, PRMT5, affects the levels of symmetric dimethylarginine (SDMA) at Arg-3 on histone H4, leading to the repression of genes which are related to disease progression in lymphoma and leukemia.
|
28874563 |
2017 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Collectively, our data support a novel leukemogenic mechanism in AML where PRMT5 mediates both silencing and transcription of genes that participate in a 'yin-yang' functional network supporting leukemia growth.
|
26536822 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
|
27643437 |
2016 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, forced expression of PRMT5 in HSPCs from LSL-K-rasG12D/CreER-Fanca-/- mice prolongs oncogenic response and delays leukemia development in recipient mice.
|
27507053 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The requisite role for PRMT5 in the context of multiple lymphoma/leukemia oncogenic drivers suggests a molecular rationale for therapeutic development.
|
25582697 |
2015 |